Seema Harichand-Herdt, MD
Hematology & Oncology · Des Moines, IANPI 1801831870
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,438 of the $2,083 with a category attached, or 69.0%. E.r. Squibb & Sons, L.L.C. accounts for 69.0% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $1,502, 5.8 times the $257 reported in 2019.
Across 12 payments — averaging $173.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$1K
- Blueprint Medicines Corporation$134
- AstraZeneca$132
- Pfizer$125
- Takeda Pharmaceuticals U.S.A., Inc.$125
- Stemline Therapeutics Inc.$65
- plus $65 from 3 others
Across 49 payments — averaging $10,433 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$344K
- Novartis$75K
- Roche Products Limited$68K
- Hoffmann-la Roche Limited$15K
- Pfizer$10K
What the payments were for
- Consulting fees$1,43869%
- Food & beverage$62730%
- Education$191%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 1 | $1,438 |
| Blueprint Medicines Corporation | 1 | $134 |
| AstraZeneca | 2 | $132 |
| Pfizer | 1 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $125 |
| Stemline Therapeutics Inc. | 2 | $65 |
| Genentech USA, Inc. | 2 | $41 |
| Boston Scientific | 1 | $13 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,083 in reported general payments places this provider in the 70th percentile of 75 hematology & oncology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 71 | $1,079,513 |
| RevlimidLenalidomide | 20 | $335,840 |
| CalquenceAcalabrutinib Maleate | 19 | $288,208 |
| CabometyxCabozantinib S-Malate | 11 | $282,848 |
| ImbruvicaIbrutinib | 13 | $213,656 |
| TagrissoOsimertinib Mesylate | 11 | $186,836 |
| VerzenioAbemaciclib | 11 | $159,677 |
| GilotrifAfatinib Dimaleate | 13 | $151,801 |
| CreonLipase/Protease/Amylase | 14 | $44,472 |
| EliquisApixaban | 55 | $37,147 |
| VenclextaVenetoclax | 13 | $27,041 |
| Abiraterone Acetate | 18 | $18,596 |
| KonvomepOmeprazole/Sodium Bicarbonate | 12 | $17,118 |
| Anastrozole | 350 | $4,717 |
| Olanzapine | 116 | $4,550 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence, Tagrisso | $132 | $475,04430 claims |
| PfizerEliquis | $125 | $37,14755 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 75 hematology & oncology providers in Iowa.
Other hematology & oncology in Des Moines
- Charles LinkDes Moines$1K
- Bradley LairDes Moines$603
- Roy MolinaDes Moines$125
- Sakeer HussainCouncil Bluffs$74K
- Usha PerepuIowa City$70K
- Umang SwamiIowa City$54K
- Umar FarooqIowa City$30K
- Brian LinkIowa City$26K
- Mark KarwalIowa City$25K
- Kartik AnandWest Des Moines$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.